ASCO 2013

CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell hear

CHICAGO— Overall survival improved by more than two-thirds in patients with metastatic melanoma randomised to have GM-CSF added to their ipilimumab therapy. A phase II study in 245 previously treated

CHICAGO—A new approach to dealing simultaneously with several of the identified molecular processes taking place in cancer has brought new prospects for extending life in patients with advanced non sm

CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizuma

CHICAGO—Patients with oropharyngeal cancer pose no risk of passing HPV infection to their spouses or partners — according findings presented at the 2013 meeting of the American Society of Clinical Onc

CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Ca

ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effec

ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months